
|Videos|December 12, 2021
Expert Addresses How Addition of Umbralisib, Ublituximab Could Affect Treatement with Ibrutinib
Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses how the addition of umbralisib and ublituximab affect those being treated with ibrutinib.
Advertisement
In a Pharmacy Times® interview, Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discussed her ASH 2021 presentation, A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.
She addressed how the addition of umbralisib and ublituximab affect those being treated with ibrutinib.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Building the pharmacy of the future — trust, loyalty, and growth
2
FDA Approves XFG-Adapted COVID-19 Vaccine, mRNA for the 2026-2027 Season
3
Oral GLP-1s Expand Obesity Treatment Options in 2026
4
Understanding Axatilimab's Mechanism in the Context of Multiple Lines of Therapy
5


































































































